Drug Trial Radar · NCT05888922
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
520
Planned (sponsor's estimate)
Start
Oct 17, 2024
Primary completion
Oct 2026
Study completion Nov 16, 2026
Sponsor
- Lead sponsor
- Industrial Farmacéutica Cantabria, S.A.Industry
- Sponsor type
- Industry
- Collaborators
- Bioskin GmbH; Astrum CRO, S.L.
- First posted
- Jun 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III clinical trial is evaluating whether oral minoxidil 1 mg is an effective and safe treatment for women with androgenetic alopecia (female pattern hair loss). Approximately 520 women is planned to take part in the study. Participants will be randomly assigned to receive either oral minoxidil, topical minoxidil 2% solution, or placebo. Neither the participants nor the study staff will know which treatment has been assigned. The study will last up to 36 weeks, including a treatment period of 24 weeks and a follow-up period. Participants will attend regular study visits to assess hair growth and monitor safety. Site investigators will evaluate changes in hair growth and hair density using scalp imaging, investigator assessments, and participant questionnaires. Safety will be monitored through physical examinations, vital signs, laboratory tests, electrocardiograms, and the recording of side effects throughout the study.
Conditions
- Androgenetic Alopecia
- Female Pattern Baldness
Interventions
Minoxidil TabletsDrug
The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Minoxidil TopicalDrug
The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Placebo oral tabletDrug
The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Vehicle solutionDrug
The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Target Area non vellus Hair Counts (TAHC)Time frame: From baseline to week 24
Locations
27 sites in 4 countries. Site status is shown where the registry gives one.
Fachklinik Bad Bentheim Klinisches Studienzentrum
Bad Bentheim, Germany
CRC - Charité Universitätsmedizin Berlin Clinical Research Center for Hair and Skin Science
Berlin, Germany
emovis by Futuremeds GmbH
Berlin, Germany
Klinische Forschung Berlin Mitte GmbH
Berlin, Germany
Hautzentrum im Jahrhunderthaus
Bochum, Germany
Rosenpark Reasearch GmbH
Darmstadt, Germany
Klinische Forschung Dresden GmbH
Dresden, Germany
Privatpraxis Dr. Hilton & Partner
Düsseldorf, Germany
Klinik für Dermatologie, Venerologie und Allergologie - Universitätsmedizin Frankfurt
Frankfurt, Germany
Dermaticum - Privatpraxis für Dermatologie
Freiburg im Breisgau, Germany
Eurofins bioskin - Research Center Dermatology
Hamburg, Germany
Klinische Forschung Hamburg GmbH
Hamburg, Germany
Klinische Forschung Hannover Mitte GmbH
Hanover, Germany
Klinische Forschung Karlsruhe GmbH
Karlsruhe, Germany
Siteworks - Zentrum für klinische Studien Karslruhe
Karlsruhe, Germany
Siteworks - Prüfzentrum Lohne
Löhne, Germany
Haut-und Lasercentrum - Dr. Tanja Fischer und Kollegen
Potsdam, Germany
SGS proderm GmbH
Schenefeld, Germany
Klinische Forschung Schwerin Gmb
Schwerin, Germany
TRIDERM Study Site Dermatological practice Dr. Leitz and colleagues
Stuttgart, Germany
Università Sapienza di Roma Dipartimento di Scienze Cliniche Internistiche Anestesiologiche e Cardiovascolari U.O.C. di Dermatologia Centro per lo studio sulla fisiopatologia degli Annessi Cutanei Sapienza Università di Roma
Roma, Italy
Hospital CUF Descobertas - Ensaios Clínicos
Lisbon, Portugal
Personal Derma - Clínica Dermatológica & Estética
Lisbon, Portugal
Instituto Dermatológico da Madeira - Dermatologia e Laserterapia
Madeirã, Portugal
Hospital Clinic de Barcelona
Barcelona, Spain
Clínica Grupo Pedro Jaén
Madrid, Spain
Institut Medico Ricart (IMR)
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.